Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCRX.L Regulatory News (CRX)

  • There is currently no data for CRX

Directorate Change

25 Feb 2009 07:00

RNS Number : 8182N
Cyprotex PLC
25 February 2009
 



25 February 2009

Cyprotex PLC ('Cyprotex' or the 'Company')

Directorate changes

Cyprotex PLC (AIM: CRX) today announces the resignation of David Evans as a Non-executive Director of the Company with immediate effect and the appointment of John Dootson as Chief Financial Officer effective from 2 March 2009.

Commenting on the directorate changes, Steve Harris, Chairman of Cyprotex said: 

"David has made a significant contribution to the Company as a Non-executive Director and the Board would like to thank him for his contribution to the Company and wish him well with his future endeavours. 

The Company is very pleased to appoint John Dootson as Chief Financial Officer. John has been associated with the Company for over four years as a consultant Financial Controller and therefore has intimate knowledge of the Company's business and finances. He brings to the Company wide ranging financial expertise gained in both industry and private practice"

Notes for Editors: 

John Dootson, aged 47, has 25 years experience in both professional practice and in industry. Trained with Tenon and Ernst & Young, John has extensive managerial experience in major accounting practices and has worked on a wide range of projects including London Stock Exchange flotations and circulars, corporate governance, company acquisitions and disposals and specialist advice to growing SMEs. John has also worked in a number of roles in Industry at Financial Controller and Director level, including seven years within the senior head office finance team of BTP plc, a former FTSE250 specialty chemical manufacturer with over 50 sites worldwide prior to its sale to Clariant AG for £1.1bn.

John is a Fellow of the Institute of Chartered Accountants in England and Wales and for the last four years he has assisted Cyprotex in a management consultative role that has included all aspects of finance and reporting.

The following information relating to Mr. Dootson is provided in compliance with the provisions of Rule 17, Schedule Two, paragraph (g) of the AIM Rules for Companies

 

Full name and age: John Kevin Dootson, age 47.

Present directorships: Downham Mayer Clarke Limited

 

Directorships during the past five years:  Downham Mayer Clarke Limited

Mr. Dootson has not been a director of any company which has been wound up or placed in administration or receivership.

Mr. Dootson holds no shares in the Company. 

There are no further disclosures to be made in respect of Mr. Dootson under the provisions of Rule 17, Schedule Two, paragraph (g) of the AIM Rules for Companies.

 

Enquiries:

Cyprotex PLC

 

Tony BaxterCEO 

01625 505100

Mark WarburtonCompany Secretary

 

Noble & Company Limited

 

John Llewellyn-Lloyd 

 02077632200

Sam Reynolds

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOATIMATMMITBJL
Date   Source Headline
7th Apr 20164:11 pmRNSForm 8.3 - Cyprotex PLC
7th Apr 20161:42 pmRNSForm 8.3 - Cyprotex
7th Apr 20169:37 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
6th Apr 20169:19 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
5th Apr 20163:10 pmRNSForm 8.3 - Cyprotex PLC
5th Apr 20169:30 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
4th Apr 201612:36 pmBUSForm 8.3 - Cyprotex Plc
4th Apr 201612:01 pmRNSForm 8.3 - Cyprotex plc
4th Apr 201610:32 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
4th Apr 201610:31 amPRNForm 8.3 - Cyprotex Plc
1st Apr 20163:58 pmRNSForm 8.3 - Cyprotex Plc
1st Apr 20167:02 amRNSStrategic Review
1st Apr 20167:01 amRNSNotice of General Meeting
1st Apr 20167:00 amRNSFinal Results
31st Mar 201610:58 amRNSLaunch of Advanced 3D Liver Model
29th Mar 20167:00 amRNSChanges to UK reporting framework
9th Mar 20167:00 amRNSLaunch of New Chemical and Cosmetics Testing Guide
10th Feb 20167:00 amRNSStrategic partnering deal with Cytocentrics
21st Jan 20167:00 amRNSExecutive Option Scheme
17th Dec 20159:09 amRNSTrading Update
17th Nov 20157:00 amRNSLaunch of Solution to Predict Preclinical Toxicity
23rd Oct 20157:00 amRNSTrading Update
15th Oct 20157:00 amRNSLaunch of New ADME Guide
13th Oct 20157:00 amRNSPartnership in the EC funded EU-ToxRisk consortium
8th Oct 20157:00 amRNSConversion of Loan Notes, Directors Dealing & TVR
21st Sep 20158:40 amRNSHolding(s) in Company
19th Aug 201512:02 pmRNSHolding(s) in Company
18th Aug 20157:00 amRNSInterim Results 2015
16th Jul 20157:00 amRNSLaunch of new Biosciences division
14th Jul 20157:00 amRNSLaunch of new chemPK workflow solution
10th Jul 201510:32 amRNSHolding(s) in Company - REPLACEMENT
10th Jul 201510:29 amRNSHolding(s) in Company - REPLACEMENT
9th Jul 20151:01 pmRNSHolding(s) in Company
9th Jul 20151:00 pmRNSHolding(s) in Company
17th Jun 201510:26 amRNSResult of AGM
1st Jun 20157:00 amRNSTrading Update
22nd May 20157:00 amRNSPublication of Annual Report & Notice of AGM
6th May 20157:02 amRNSHolding(s) in Company
15th Apr 20157:00 amRNSFinal Results
14th Apr 20157:00 amRNSLaunch of in vitro service using 3D microtissues
31st Mar 20157:00 amRNSLaunch of new laboratory in its US facility
19th Mar 20157:00 amRNSLaunch of Short Time Exposure Service
12th Mar 20157:00 amRNSAppointment of Leader of Drug Transporter Team
22nd Dec 201412:12 pmRNSDirector Dealing
19th Nov 20141:26 pmRNSDirector Dealing 19 November 2014
14th Nov 20143:34 pmRNSDirector Dealing 14 November 2014
14th Nov 20147:00 amRNSTrading Update
13th Nov 20145:17 pmRNSHolding(s) in Company
14th Oct 20147:00 amRNSEnhanced SenCeeTox® technology
13th Oct 20142:14 pmRNSConversion of Loan Notes & TVR (Replacement)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.